Monday, April 11, 1994
Revisiting cost-benefit for CentoRx
Virtually all drugs have side effects, and ultimately clinicians have to weigh the
benefit of using a product versus its side-effect profile. The issue was highlighted last
week by an editorial accompanying the publication in the New England Journal of
Medicine of the data from Centocor Inc.'s Phase III study of its CentoRx antibody
fragment to prevent complications in high-risk angioplasty patients.
Laurence Harker, professor of medicine and division director of hematology/oncology at
the Department of Medicine at Emory University, said that while use of CNTO's IIb/IIIa
platelet inhibitor is an appealing strategy, the EPIC study also shows the importance of
assessing concurrent risks of hemorrhage in antithrombotic therapies.